Hepatology Highlights

Nicholas W. Russo, Robert S. Brown, Gopanandan Parthasarathy, Robert E. Schwartz, Adam Buckholz, Arun B. Jesudian, Enis Kostallari, Cesar Taborda, Joel Wedd, Tejasav S. Sehrawat, Navid Hejazifar, Lauren M. Yang, Daryl T.Y. Lau, Jessica Maiers, Nidhi Jalan‐Sakrikar – 6 November 2020

Hepatology Highlights

Nicholas W. Russo, Robert S. Brown, Gopanandan Parthasarathy, Robert E. Schwartz, Adam Buckholz, Arun B. Jesudian, Enis Kostallari, Cesar Taborda, Joel Wedd, Tejasav S. Sehrawat, Navid Hejazifar, Lauren M. Yang, Daryl T.Y. Lau, Jessica Maiers, Nidhi Jalan‐Sakrikar – 6 November 2020

Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB

Maximilian Wübbolding, Juan Carlos Lopez Alfonso, Chun‐Yen Lin, Sebastian Binder, Christine Falk, Jennifer Debarry, Paul Gineste, Anke R.M. Kraft, Rong‐Nan Chien, Benjamin Maasoumy, Heiner Wedemeyer, Wen‐Juei Jeng, Michael Meyer Hermann, Markus Cornberg, Christoph Höner zu Siederdissen – 5 November 2020 – Treatment with nucleos(t)ide analogues (NAs) may be stopped after 1‐3 years of hepatitis B virus DNA suppression in hepatitis B e antigen (HBeAg)‐negative patients according to Asian Pacific Association for the Study of Liver and European Association for the Study of Liver guidelines.

Addressing Social Determinants of Liver Disease During the COVID‐19 Pandemic and Beyond: A Call to Action

Ani Kardashian, Julius Wilder, Norah A. Terrault, Jennifer C. Price – 4 November 2020 – The COVID‐19 pandemic has exposed healthcare inequities in the USA and highlighted the importance of social conditions in shaping the health of persons. In the field of hepatology, social determinants of health (SDOH) are closely linked to disparities in liver disease prevalence, outcomes, and access to treatment.

Subscribe to